

您的位置: [首页](#)>> [文章摘要](#)[中文](#) [English](#)

他莫昔芬治疗进展期肝癌的系统评价

龚文锋, 黎乐群, 钟鉴宏, 游雪梅, 马良, 彭宁福, 向邦德, 张秋明

530021 南宁, 广西医科大学附属肿瘤医院肝胆外科(龚文锋、黎乐群、钟鉴宏、游雪梅、马良、医院高级病区(张秋明)

黎乐群, Email:lilequn_gongwf@163.com

国家自然科学基金(81160262/H1602)

摘要: 目的 评价他莫昔芬治疗进展期肝癌的疗效及安全性。方法 计算机检索Cochrane Library等数据库关于他莫昔芬治疗进展期肝癌的随机对照研究, 对纳入过叙述的形式进行评价。结果 纳入10篇随机对照试验共1712例患者, 在1年生存率对照组比较差异无统计学意义, 只有2个研究认为差异有统计学意义。结论 他莫昔芬研究当中也不作为对照剂使用。

关键词: 癌, 肝细胞; 受体, 雌激素; 他莫昔芬; 系统评价文献标引: 龚文锋, 黎乐群, 钟鉴宏, 游雪梅, 马良, 彭宁福, 向邦德, 张秋明. 他莫昔芬治疗师杂志: 电子版, 2012, 6(24):8180-8184. [复制](#)

参考文献:

[1] Shi HY, Lee KT, Lee HH, et al. Comparison of Artificial Neural Network Models for Predicting In-Hospital Mortality after Primary Liver Cancer [PubMed]

[2] 方志雄, 程丹, 方志宏, 等. 肝动脉化疗栓塞联合射频消融治疗大肝癌疗效评价. 2012, 6:2823-2825.

[3] 卢欣, 徐意瑶, 杨华瑜, 等. 肝细胞肝癌术后复发时间对再次手术预后的影响. 2012, 6:6269-6272.

[4] Kamiyama T, Nakanishi K, Yokoo H, et al. Analysis of the risk factors for recurrence or progression within 1 year after hepatectomy in patients with

期刊导读

7卷3期 2013年2月 [最新]



期刊存档

期刊存档

[查看目录](#)

期刊订阅



在线订阅



邮件订阅



RSS

作者中心



资质及晋升信息



作者查稿



写作技巧



投稿方式



作者指南

编委会

期刊服务



建议我们



会员服务



广告合作



继续教育

[5] 张金辉,阿伊甫汗·阿汗,张日新,等.经皮无水酒精治疗直径 ≤ 3 cm肝癌的志, 2009, 9:695-704.

[6] Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency resection in the treatment of small hepatocellular carcinoma. J Hepatol,

[7] A comparison of lipiodol chemoembolization and conservative treatment of hepatocellular carcinoma. N Engl J Med, 1995, 332:1256-1261. : [\[PubMed\]](#)

[8] Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma. Cancer, 2004, 40:1474-1484. : [\[PubMed\]](#)

[9] Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma. Cancer Res, 2006, 66:11851-11858. : [\[PubMed\]](#)

[10] Nagasue N, Kohno H, Chang Y, et al. Specificity of androgen receptor expression in the liver in humans. Hepatogastroenterology, 1990, 37:474-479. : [\[PubMed\]](#)

[11] Jonas S, Bechstein WO, Heinze T, et al. Female sex hormone receptor expression in hepatocellular carcinoma and outcome after surgical resection. Surgery, 1999, 125:100-105.

[12] Perrone F, Gallo C, Daniele B, et al. Tamoxifen in the treatment of advanced hepatocellular carcinoma: results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Biotechnol, 2007, 8:101-106.

[13] Barbare JC, Milan C, Bouche O, et al. Treatment of advanced hepatocellular carcinoma with tamoxifen: a phase III trial in 420 patients [abstract 551]. Proc Am Soc Clin Oncol, 2005, 23:165a.

[14] Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of advanced hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology, 2002, 36:100-105.

[15] Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep, 1987, 71:100-105.

[16] Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a blind placebo-controlled trial in 120 patients. Gastroenterology, 1995, 109:100-105.

[17] Perrone F, Gallo C, Daniele B, et al. Tamoxifen in the treatment of advanced hepatocellular carcinoma: results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Biotechnol, 2007, 8:101-106.

[18] Coll S, Sola R, Vila M, et al. Treatment with tamoxifen in advanced hepatocellular carcinoma. Results of a randomized placebo controlled trial [abstract]. Hepatology, 2005, 41:100a.

[19] Riestra S, Rodriguez M, Delgado M, et al. Tamoxifen does not improve survival in advanced hepatocellular carcinoma. J Clin Gastroenterol, 1998, 26:200-203.

[20] Martínez Cerezo FJ, Tomás A, Donoso L, et al. Controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Gastroenterol, 1998, 26:200-203.

advanced hepatocellular carcinoma. J Hepatol, 1994, 20:702-706. :[\[PubMed\]](#)

[21] Liu CL, Fan ST, Ng IO, et al. Treatment of advanced hepatocellular carcinoma: correlation with expression of hormone receptors: a prospective randomized trial. Gastroenterol, 2000, 95:218-222. :[\[PubMed\]](#)

[22] Elba S, Giannizzi V, Misciagna G, et al. Randomized controlled trial of inoperable hepatocellular carcinoma. Ital J Gastroenterol, 1994, 26:66-68.

[23] Barbare JC, Bouché O, Bonnetain F, et al. Randomised controlled trial of inoperable hepatocellular carcinoma. J Clin Oncol, 2005, 23:4338-4346. :[\[PubMed\]](#)

[24] Clavière C, Bronowicki JP, Hudziak H, et al. Role of sex steroids in the pathophysiology of hepatocellular carcinoma. Gastroenterol Clin Biol, 1999, 23:101-106.

[25] Francavilla A, Polimeno L, DiLeo A, et al. The effect of estrogen on cell proliferation in vivo and in vitro. Hepatology, 1989, 9:614-620. :[\[PubMed\]](#)

[26] Tan CK, Chow PK, Findlay M, et al. Use of tamoxifen in hepatocellular carcinoma: a paradigm shift. J Gastroenterol Hepatol, 2000, 15:725-729. :[\[PubMed\]](#)

循证医学

霉酚酸酯与环磷酰胺治疗重型狼疮肾炎的Meta分析

蔡晓懿, 夏正坤, 张莹, 刘梦圆, 李静, 张婕. 中华临床医师杂志: 电子版 2012;6(24):8160-8166.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)